Avistone nabs $200M cancer platform funding drive from leading VCs as it combines with Pearl Biotechnews2021-12-07T09:13:18+00:00December 7th, 2021|FierceBiotech|
GlaxoSmithKline, Medicago hit 75% efficacy against delta COVID strain, but omicron muddies watersnews2021-12-06T19:55:55+00:00December 6th, 2021|FierceBiotech|
Apple Tree Partners breaks into UK with biotech Adendra Therapeutics launch, $53M series A raisenews2021-12-06T18:42:00+00:00December 6th, 2021|FierceBiotech|
Could Viagra prevent and treat Alzheimer’s? Cleveland Clinic team shows its potentialnews2021-12-06T14:57:25+00:00December 6th, 2021|FierceBiotech|
Biohaven pain spray aces test as C-suite shake-up sees incoming CFO, chief in chairman rolenews2021-12-06T14:48:15+00:00December 6th, 2021|FierceBiotech|
Investors punish Aeglea for missed rare disease secondaries, sending stock spiraling despite primary endpoint successnews2021-12-06T13:58:23+00:00December 6th, 2021|FierceBiotech|
Adicet soars on early responses to gamma delta CAR-T therapynews2021-12-06T13:19:54+00:00December 6th, 2021|FierceBiotech|
OncoMyx nabs $50M to jump into the clinic with its rabbit pox virus cancer drugnews2021-12-06T10:07:42+00:00December 6th, 2021|FierceBiotech|
Genetic variant linked to Amish community could pave way for new heart disease therapiesnews2021-12-05T22:48:44+00:00December 5th, 2021|FierceBiotech|
Gene therapy startup bursts forth from incubation at J&J and F-Prime, graduating with $80M and a Novartis veteran at the helmnews2021-12-03T12:24:57+00:00December 3rd, 2021|FierceBiotech|
